Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
News|Articles|May 1, 2018
Wyatt Technology Announces Executive Team Changes
Author(s)Pharmaceutical Technology Editors
Geofrey Wyatt has been named CEO and Clifford Wyatt named president of Wyatt Technology.
Advertisement
Wyatt Technology, a developer of instrumentation for absolute macromolecular and nanoparticle characterization, announced changes to its executive team on May 1, 2018.
Geofrey Wyatt was named chief executive office, and Clifford Wyatt was named president. Philip Wyatt, who founded the company almost 40 years ago, will become chairman of the board and take on a more passive role, the company reported in a press statement.
The company also announced that Michelle Chen was promoted to vice-president of analytical services and will join the executive team.
Source:
Advertisement
Related to this article
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
5